Arylpiperazinyl compounds
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formulae I: and II, and synthesis and uses of those compounds for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
-
Citations
57 Claims
- 1. A compound having the formula
-
14. 4-Methyl-N-{4-[4-(3-nitro-phenyl)-piperazin-1-yl]-butyl}-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
15. 4-Methyl-N-{4-[4-(3-nitro-phenyl)-piperazin-1-yl]-butyl}-benzenesulfonamide HCl.
-
16. N-(3-{4-[4-(Toluene-4-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-butyramide;
- or pharmaceutically acceptable salts thereof.
-
17. 2,2-Dimethyl-N-(3-{4-[4-(toluene-4-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-propionamide;
- or pharmaceutically acceptable salts thereof.
-
18. N-(3-{4-[4-(Toluene-4-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-isobutyramide;
- or pharmaceutically acceptable salts thereof.
-
19. N-{4-[4-(3-Ethanesulfonylamino-phenyl)-piperazin-1-yl]-butyl}-4-methyl-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
20. 4-Methyl-N-(4-{4-[3-(propane-2-sulfonylamino)-phenyl]-piperazin-1-yl}-butyl)-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
21. 4-Methyl-N-{4-[4-(3-nitro-phenyl)-piperazin-1-yl]-butyl}-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
22. N-{4-[4-(2-Methoxy-5-nitro-phenyl)-piperazin-1-yl]-butyl}-4-methyl-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
23. N-{4-[4-(3-Methoxy-phenyl)-piperazin-1-yl]-butyl}-4-methyl-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
24. N-{4-[4-(3-Ethanesulfonylamino-phenyl)-piperazin-1-yl]-butyl}-4-methyl-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
25. N-{4-[4-(3-Methanesulfonylamino-phenyl)-piperazin-1-yl]-butyl}-4-methyl-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
26. N-[4-(4-Biphenyl-3-yl-piperazin-1-yl)-butyl]-4-methyl-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
27. 4-Methyl-N-[4-(4-phenyl-piperazin-1-yl)-butyl]-benzenesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
28. 1-cyclohexyl-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)methanesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
29. N-(3-{4-[4-(Toluene-4-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-propionamide;
- or pharmaceutically acceptable salts thereof.
-
30. (3-{4-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-ylmethyl]-piperazin-1-yl}-phenyl)-dimethyl-amine;
- or pharmaceutically acceptable salts thereof.
-
31. 1-cyclohexyl-N-(4-(4-(3-(dimethylamino)phenyl)piperazin-1-yl)butyl)methanesulfonamide;
- or pharmaceutically acceptable salts thereof.
-
32. N-(3-{4-[1-(4-Fluoro-benzenesulfonyl)-piperidin-4-ylmethyl]-piperazin-1-yl}-phenyl)-acetamide;
- or pharmaceutically acceptable salts thereof.
-
33. N-(3-{4-[4-(4-Fluoro-benzenesulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-acetamide;
- or pharmaceutically acceptable salts thereof.
-
34. 1-(2-Methoxy-phenyl)-4-[1-(toluene-4-sulfonyl)-piperidin-3-ylmethyl]-piperazine;
- or pharmaceutically acceptable salts thereof.
- 35. A compound having the formula
-
45. Cyclopropanecarboxylic acid (3-{4-[4-(toluene-4-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-amide;
- or pharmaceutically acceptable salts.
-
46. N-(3-{4-[4-(Toluene-4-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-acetamide;
- or pharmaceutically acceptable salts thereof.
-
47. N-{3-[4-(4-Cyclohexylmethanesulfonylamino-butyl)-piperazin-1-yl]-phenyl}-acetamide;
- or pharmaceutically acceptable salts thereof.
-
48. N-{3-[4-(1-Cyclohexylmethanesulfonyl-piperidin-4-ylmethyl)-piperazin-1-yl]-phenyl}-acetamide;
- or pharmaceutically acceptable salts thereof.
-
49. Cyclopropanecarboxylic acid {3-[4-(4-cyclohexylmethanesulfonylamino-butyl)-piperazin-1-yl]-phenyl}-amide;
- or pharmaceutically acceptable salts thereof.
-
50. N-(3-{4-[1-(Propane-2-sulfonyl)-piperidin-4-ylmethyl]-piperazin-1-yl}-phenyl)-acetamide;
- or pharmaceutically acceptable salts thereof.
-
51. N-(3-{4-[4-(Propane-2-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-acetamide;
- or pharmaceutically acceptable salts thereof.
-
52. N-{3-[4-(4-Cyclohexanesulfonylamino-butyl)-piperazin-1-yl]-phenyl}-acetamide;
- or pharmaceutically acceptable salts thereof.
-
53. N-(3-{4-[4-(Cyclohexylmethanesulfonyl-methyl-amino)-butyl]-piperazin-1-yl}-phenyl)-acetamide;
- or pharmaceutically acceptable salts thereof.
-
54. N-(3-{4-[4-(2-Methyl-propane-1-sulfonylamino)-butyl]-piperazin-1-yl}-phenyl)-acetamide;
- or pharmaceutically acceptable salts thereof.
-
55. N-[3-(4-{4-[Methyl-(2-methyl-propane-1-sulfonyl)-amino]-butyl}-piperazin-1-yl)-phenyl]-acetamide;
- or pharmaceutically acceptable salts thereof.
Specification